Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
7
×
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
merck
7
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
7
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
eli lilly
fda
bristol-myers squibb
cancer immunotherapy
moderna
pfizer
startups
abbvie
alzheimer's disease
deals
What
bio
roundup
companies
drug
new
approved
fda
growing
life
nash
news
science
time
week
advantages
alliance
approval
arena’s
bar
biogen’s
biopharmaceutical
black
bounty
brings
bristol
buy
calls
cancer
changing
cig
color
comeback
continue
convo
corner
crispr
days
deals
debut
deeper
Language
unset
Current search:
cancer
×
" san francisco top stories "
×
merck
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More